Agilent Technologies acquired Seahorse Bioscience for approximately $242 million, a transaction completed in November 2015, structured as all cash.
Seahorse Bioscience operates in Life Sciences and Applied Markets, is based in North Billerica, Massachusetts, USA. Seahorse Bioscience makes instruments and assay kits that measure cell metabolism and bioenergetics in real time. Its XF technology gives researchers kinetic data on cell health and function and how cells respond to disease and drug treatment.
Seahorse's metabolism-measurement tools complemented Agilent's separations and mass-spectrometry platforms, broadening its toolset for metabolomics and disease research.
Seahorse Bioscience's unique technology is the perfect complement to Agilent's market-leading separations and mass spectrometry solutions, in particular for metabolomics research and disease research in pharma.Patrick Kaltenbach, President, Agilent Life Sciences and Applied Markets Group
Advisory firms were not disclosed for this transaction.